In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are commonly overactivated in human cancers. He also speaks to the company’s services business, which has more than a decade of experience partnering with pharmaceutical companies to help them understand the biological mechanisms behind their medicines using rigorous, reproducible methods for data analysis and quality control.
